Key facts
- This page summarizes Thomas K. Equels's Form 4 filing for AIM ImmunoTech Inc. (AIM).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 26 Oct 2026, 12:12.
Thomas K. Equels - 23 Oct 2026 Form 4 Insider Report for AIM ImmunoTech Inc. (AIM)
- Reporting relationship
- CEO & President, Director
- Issuer ticker
- AIM
- Reported as of
- 23 Oct 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 26 Oct 2026, 12:12:12 UTC
- Prior SEC filing
- 23 Oct 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Thomas K Equels
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Thomas K. Equels filed Form 4 for AIM ImmunoTech Inc. (AIM) on 26 Oct 2026.
Change
- Previous filing in this sequence was filed on 23 Oct 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001450324
Primary reporting owner
Equels Thomas K
- Relationship
- CEO & President, Director
- Address
- 2117 SOUTHWEST HIGHWAY 484, OCALA,
- Signature
- /s/ Thomas K Equels
- Signature date
- 26 Oct 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AIM
transaction
Common Stock
Purchase
- Transaction value
- Shares
- +31,675
- Change %
- +20%
- Price
- $0.1600*
- Shares after
- 189,747
- Date
- 23 Oct 2026
- Ownership
- Direct
* marks a reported price that did not pass the local price check.